Abbott Laboratories (FRA:ABL)
Germany · Delayed Price · Currency is EUR | Market Cap | 149.90B -24.3% |
| Revenue (ttm) | 40.78B +8.1% |
| Net Income | 4.73B -61.2% |
| EPS | 2.71 -61.2% |
| Shares Out | n/a |
| PE Ratio | 31.71 |
| Forward PE | 16.68 |
| Dividend | 2.18 (2.55%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | n/a |
| Open | 85.68 |
| Previous Close | 87.06 |
| Day's Range | 85.68 - 85.68 |
| 52-Week Range | 69.76 - 115.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott announces FDA approval of new CardioMEMS HF System
Abbott (ABT) announced U.S. FDA approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care teams can…
Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can sig...
Abbott upgraded to Buy from Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn upgraded Abbott (ABT) to Buy from Neutral with a price target of $127, up from $119. The company’s acquisition of Exact Sciences has strengthened its diagnostics…
Abbott hosts conference call for third-quarter earnings
ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.
Abbott announces U.S. commercial launch of SimpleScreen CRC
Abbott (ABT) announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the…
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help eligib...
Abbott, Berry Street announce exclusive partnership
Abbott (ABT) and Berry Street announced an exclusive partnership to help people take a more proactive approach to nutrition and long-term health. The partnership brings together Lingo, Abbott’s consum...
Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors...
Abbott declares 411th consecutive quarterly dividend
ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Abbott’s Volt Pulsed Field Ablation System used for first time in Canada
Abbott (ABT) announced that its Volt Pulsed Field Ablation System, designed to deliver more precise, targeted energy with fewer catheter exchanges and reduced radiation exposure than earlier-generatio...
Abbott confirms agreement with DOJ to resolve 2022 formula recall claims
Abbott (ABT) confirmed the company has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed…
Abbott to pay $384 mln over contaminated infant formula allegations, US Justice Dept says
Abbott Laboratories has agreed to pay more than $384 million to settle allegations related to contaminated infant formula, the U.S. Justice Department said on Monday.
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government regulators of un...
Abbott to pay over $384M to settle infant formula allegations
Abbott (ABT) Laboratories has agreed to pay $384,999,040 to resolve allegations that it caused false claims to be submitted between Jan. 1, 2018, and Dec. 31, 2022, to federal and…
Abbott’s TactiFlex Duo Ablation Catheter approved by FDA
Abbott (ABT) has received FDA approval for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with challenging cases of atrial fibrillation, or AFib. Abbott will soon begin cases…
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases St...
Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support bab...
Abbott’s Amulet 360 device granted CE Mark
Abbott (ABT) has received CE Mark for the Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce risk of stroke in patients with atrial fibrillation not caused…
Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design updat...
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients
The U.S. Food and Drug Administration said on Tuesday it authorized Abbott Laboratories' glucose monitor, making it the first device that continuously monitors both ketone levels and blood sugar.
Abbott receives FDA authorization for Libre Duo 10 Day system
Abbott (ABT) announced U.S. Food and Drug Administration authorization of its Libre Duo 10 Day system, the world’s first dual glucose-ketone sensing technology. The new biowearable is designed to aler...
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for...
Abbott agrees to $670 million settlement of infant formula cases
Abbott said on Thursday it reached a $670 million settlement with three law firms to resolve legal claims by 2,000 people who alleged harms relating to the company's specialty formulas for preterm i...
Abbott resolves portion of litigation regarding specialty infant formulas
Abbott (ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company’s specialty formulas for preterm in...